Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Bearish Signals

Technical Trend Overview and Price Movement

The pharmaceutical giant, currently trading at ₹1,171.00, has seen its technical trend downgrade from mildly bearish to bearish. The stock’s intraday range on 2 Sep 2026 was between ₹1,167.85 and ₹1,179.90, closing slightly above the previous close of ₹1,165.00. While this marginal uptick might appear positive, the underlying technical indicators paint a more cautious picture.

Over the past 52 weeks, Dr Reddys Laboratories has traded between a low of ₹1,080.05 and a high of ₹1,414.40, reflecting significant volatility within the mid-cap pharmaceuticals sector. The current price sits closer to the lower end of this range, indicating potential resistance to upward momentum.

MACD and Moving Averages Signal Bearish Momentum

The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart and mildly bearish on the monthly chart. This suggests that the stock’s short-term momentum is weakening, with the MACD line below the signal line, indicating selling pressure. Complementing this, the daily moving averages also confirm a bearish stance, with the stock price trading below key moving averages such as the 50-day and 200-day lines, signalling a downtrend.

Such alignment across multiple timeframes underscores the risk of further downside, as moving averages often act as dynamic resistance levels. Investors should note that the bearish MACD and moving averages typically precede price declines or consolidation phases.

RSI and Bollinger Bands: Mixed Signals but Leaning Bearish

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory without indicating overbought or oversold conditions. This neutrality suggests that momentum is not yet extreme in either direction, but it also fails to provide a bullish counterpoint to other bearish indicators.

Bollinger Bands, which measure volatility and price levels relative to moving averages, show bearish signals on the weekly chart and mildly bearish on the monthly chart. The stock price is closer to the lower band on the weekly timeframe, indicating downward pressure and potential continuation of the bearish trend. This is consistent with the overall technical deterioration observed.

Additional Technical Indicators Confirm Bearish Bias

The Know Sure Thing (KST) indicator, which aggregates multiple rate-of-change calculations, is bearish on the weekly chart and mildly bearish on the monthly chart. This further supports the view of weakening momentum and potential for continued price declines.

On the volume front, the On-Balance Volume (OBV) indicator is bearish on the weekly timeframe, signalling that volume trends are not supporting price advances. The lack of volume confirmation often precedes price weakness, as it indicates selling pressure outweighs buying interest.

Interestingly, the Dow Theory presents a mildly bullish signal on the weekly chart but shows no clear trend on the monthly chart. This divergence suggests some short-term optimism among market participants, but it is insufficient to offset the broader bearish technical consensus.

Comparative Returns and Market Context

When analysing Dr Reddys Laboratories’ returns relative to the Sensex, the stock has underperformed over most time horizons. Year-to-date, the stock has declined by 7.87%, while the Sensex fell by 9.71%, indicating a slightly better relative performance. However, over the one-year period, Dr Reddys has dropped 8.54%, compared to a 4.26% decline in the Sensex, highlighting recent underperformance.

Longer-term returns show a mixed picture: a 3-year return of 4.96% lags the Sensex’s 17.67%, and a 5-year return of 22.90% trails the Sensex’s 34.19%. Over a decade, the stock has appreciated by 88.99%, significantly below the Sensex’s 170.71% gain. These figures reflect the challenges faced by the company amid sectoral and market headwinds.

Implications for Investors and Outlook

Given the current technical landscape, investors should approach Dr Reddys Laboratories with caution. The downgrade in the Mojo Grade from Hold to Sell on 13 Jul 2026, accompanied by a low Mojo Score of 30.0, reinforces the bearish sentiment. The mid-cap pharmaceutical stock’s technical indicators collectively suggest a continuation of downward momentum or at best, a period of consolidation.

While the stock’s slight daily gain of 0.52% may offer some short-term relief, the prevailing bearish signals from MACD, moving averages, Bollinger Bands, KST, and OBV indicate that downside risks remain elevated. The absence of strong RSI signals means there is no immediate indication of oversold conditions that might prompt a rebound.

Sector and Industry Considerations

Operating within the Pharmaceuticals & Biotechnology sector, Dr Reddys Laboratories faces sector-specific challenges including regulatory scrutiny, pricing pressures, and competitive innovation. The mid-cap status of the company adds an additional layer of volatility compared to large-cap peers, which may benefit from more stable earnings and diversified product portfolios.

Investors should weigh these sectoral dynamics alongside the technical signals when considering exposure to Dr Reddys Laboratories. The current technical downgrade and bearish momentum suggest that the stock may underperform relative to both its sector and the broader market in the near term.

Conclusion

In summary, Dr Reddys Laboratories Ltd is exhibiting a clear shift towards bearish technical momentum, with multiple indicators confirming a weakening trend. The downgrade in Mojo Grade to Sell and the low Mojo Score of 30.0 further underline the cautious stance warranted by the stock’s current profile. While short-term price movements show minor gains, the broader technical and volume-based indicators suggest that investors should remain vigilant and consider alternative opportunities within the pharmaceuticals sector or beyond.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →